Methylprednisolone
Methylprednisolone is an intermediate-acting synthetic glucocorticoid about five times more anti-inflammatory potent than cortisol, with negligible mineralocorticoid (salt-retaining) activity. It is widely used as high-dose IV 'pulse' therapy and as the Medrol Dosepak oral taper, and is a common depot injection for joints. Same double-edged trade-off for athletes: strong inflammation and pain relief, but catabolic and HPA-suppressive.
01 Overview
Methylprednisolone's low mineralocorticoid activity makes it preferable to prednisolone where fluid retention is a concern. It is used for severe inflammatory and autoimmune flares, spinal cord injury protocols historically, and as intra-articular depot injection (methylprednisolone acetate) for joint inflammation. The Medrol Dosepak provides a convenient pre-tapered six-day oral course.
For recovery-minded athletes, a local joint injection can quiet inflammation, but repeated intra-articular corticosteroid injections are associated with cartilage harm, and systemic use carries the full glucocorticoid liability of catabolism, immunosuppression, glucose elevation and HPA suppression. WADA prohibits it in-competition by systemic routes including injection.
02 Mechanism
Glucocorticoid receptor agonist suppressing inflammatory gene transcription with minimal mineralocorticoid activity; higher glucocorticoid potency than prednisolone.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Medrol Dosepak | 4–24 mg/day | Oral | Pre-tapered 6-day oral course; total ~84 mg tapering down. |
| Depot / intra-articular | 40–120 mg | IM | Depot acetate for joint or systemic use; effect lasts weeks. Limit repeat joint injections. |
| Pulse therapy | 500–1000 mg/day | IV | High-dose IV pulse for severe flares, typically 3 days. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Potent anti-inflammatory actionStrong suppression of inflammation with little salt/water retention. | ~5x cortisol | Clinical | |
| Local joint pain reliefIntra-articular depot injection can relieve joint inflammation for weeks. | weeks | Clinical | |
| Muscle catabolismSystemic use is catabolic to skeletal muscle. | dose/duration dependent | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| HPA axis suppressionSuppresses endogenous cortisol; depot injections can suppress the axis for weeks. | Severe | Universal with sustained use | Clinical | |
| Cartilage damage (repeat joint injection)Repeated intra-articular corticosteroid injections associated with accelerated cartilage loss. | Moderate | With repeated injections | Clinical | |
| HyperglycaemiaTransient blood glucose elevation, marked after IV pulses. | Moderate | Common | Clinical |